The author experiences premenstrual dysphoric disorder (PMDD), which affects 1-7% of menstruating individuals, including trans men and nonbinary people, causing severe emotional and physical changes. Treatments like SSRIs and birth control can help, but the diagnosis skews towards viewing the symptoms as a mental illness, thereby potentially causing unnecessary distress. Some bioethicists believe it reflects societal stress on women, rather than a mental condition. While medical support is vital, addressing societal pressures may offer better solutions.
FDA approves breast cancer drug
The FDA has approved Eli Lilly’s imlunestrant, an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor positive, HER2-negative, ESR1-mutated advanced or
